New AML Pill Replaces Hospital Visits for Older Patients

Older adults facing acute myeloid leukemia just got a lifeline that lets them fight cancer from the comfort of home instead of spending days each month tethered to an IV in a hospital.

Researchers at Weill Cornell Medicine, NewYork-Presbyterian, MD Anderson Cancer Center, and Yale University tested an all-oral treatment combining two pills—decitabine-cedazuridine and venetoclax. The results, published June 3 in the New England Journal of Medicine, showed that 46.5% of patients achieved complete remission, while 63% saw their cancer cells become undetectable.

The median survival reached 15.5 months, matching the outcomes of existing IV therapies. On May 13, the FDA approved this pill combination for adults 75 and older with newly diagnosed AML, plus younger patients too frail for intensive chemotherapy.

AML is an aggressive blood cancer particularly dangerous for older adults. Until now, the standard treatment required patients to visit clinics or hospitals for five to seven days every month to receive injectable medications alongside oral venetoclax.

Those repeated trips created exhausting physical and emotional burdens for patients already weakened by cancer. Families struggled with transportation, work schedules, and the anxiety of watching loved ones endure treatment cycles that felt endless.

The breakthrough came when pharmacologists developed a pill version of decitabine by pairing it with cedazuridine, which prevents the drug from breaking down during digestion. The 189-patient trial across the United States, Canada, and Spain proved this oral version works just as well as IV treatment.

"Patients are thrilled not to have to deal with monthly chemotherapy injections or infusions," said Dr. Gail Roboz, lead author and director of the Clinical and Translational Leukemia Program at Weill Cornell. She anticipates this will become the new standard of care.

Why This Inspires

This treatment transforms AML from a condition requiring constant hospital presence into something manageable at home. Patients can maintain remission while keeping their normal routines, spending time with family, and avoiding the physical toll of repeated hospital visits.

The research team is already working on the next frontier. They're exploring triplet therapies that add targeted drugs to the combination, aiming to drive leukemia cells so low that patients can eventually stop treatment altogether and be cured.

For now, most patients continue treatment like managing a chronic condition, but with excellent quality of life. The goal of keeping people out of hospitals while fighting cancer has become reality.